OK
OKUR.US OnKure Therapeutics, Inc.
- Market cap
- USD 113M
- P/E
- -
- P/B
- 0.69x
- ROE
- -40.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is OKUR.US undervalued?
Graham numberThe Graham number of OnKure Therapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
OnKure Therapeutics, Inc. fundamental analysis
No fundamental analysis for OnKure Therapeutics, Inc. yet.
OnKure Therapeutics, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About OnKure Therapeutics, Inc.
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and …
Full company profileOnKure Therapeutics, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
OnKure Therapeutics, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -37.0K | -50.0K | -529K | -560K | -662K | -830K | - |
| Operating Income | -19.6M | -39.8M | -29.8M | -36.9M | -54.4M | -63.0M | -69.2M |
| EBITDA | -19.4M | -39.7M | -29.1M | -34.8M | -51.7M | -58.7M | -63.6M |
| Net Income | -19.5M | -39.8M | -29.5M | -35.3M | -52.7M | -59.5M | -64.5M |
| EPS | -7.74 | -22 | -2.21 | -2.65 | -3.95 | -4.40 | -1.29 |
| Balance Sheet | |||||||
| Total Assets | 55.2M | 154M | 16.0M | 35.7M | 115M | 62.1M | 167M |
| Total Liabilities | 97.3M | 6.81M | 70.4M | 138M | 11.1M | 5.93M | 9.34M |
| Shareholders' Equity | -42.1M | 147M | -54.4M | -102M | 104M | 56.2M | 158M |
| Cash & Short-term Investments | 53.6M | 148M | 11.5M | 29.9M | 111M | 59.1M | 163M |
| Total Debt | 92.7M | - | 637K | 674K | 1.09M | 549K | 790K |
| Cash Flow | |||||||
| Operating Cash Flow | -18.5M | -38.0M | -27.0M | -34.5M | -51.1M | -51.8M | -48.5M |
| Capital Expenditure | 24.0K | 198K | 1.13M | 246K | 52.0K | 46.0K | 53.3K |
| Free Cash Flow | -18.6M | -38.2M | -28.1M | -34.8M | -51.2M | -51.9M | -48.6M |
| Ratios | |||||||
| ROE | - | -27.0% | - | - | -50.7% | -105.9% | -40.9% |
| ROA | -35.2% | -25.8% | -184.5% | -98.8% | -45.8% | -95.8% | -38.6% |
| Debt to Equity | - | - | - | - | 0.01x | 0.01x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
OnKure Therapeutics, Inc. dividends
OnKure Therapeutics, Inc. has not paid dividends in the last 6 fiscal years.
Last stock split: 1:10 on Oct 7, 2024.
Who owns OnKure Therapeutics, Inc.
- Insiders 10.32%
- Institutions 89.68%
- Public & others 0.00%
- Shares outstanding 40.5M
- Free float 18.7M
Top funds holding OKUR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.15M | 2.80% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 557K | 1.35% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 286K | 0.69% | 0.00% | Aug 2026 |
| iShares Russell 2000 Value ETF | 228K | 0.55% | 0.00% | Oct 2026 |
| Vanguard Russell 2000 ETF | 151K | 0.37% | +0.32% | Sep 2026 |
| Fidelity Extended Market Index | 135K | 0.33% | -0.38% | Sep 2026 |
| T. Rowe Price Health Care ETF | 108K | 0.26% | 0.00% | Oct 2026 |
| iShares Micro-Cap ETF | 79.5K | 0.19% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 78.0K | 0.19% | -0.05% | Sep 2026 |
| Schwab Small Cap Index | 63.6K | 0.15% | 0.00% | Sep 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 52.5K | 0.13% | 0.00% | Oct 2026 |
| Fidelity Series Total Market Index | 51.5K | 0.13% | 0.00% | Sep 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 49.0K | 0.12% | 0.00% | Sep 2026 |
| Fidelity Small Cap Value Index | 39.0K | 0.09% | +6.76% | Aug 2026 |
| Fidelity VIP Disciplined Small Cap Init | 35.7K | 0.09% | 0.00% | Aug 2026 |
| Nuveen Small Cap Blend Idx R6 | 35.4K | 0.09% | 0.00% | Sep 2026 |
| Bridge Builder Small Cap Fund | 34.8K | 0.08% | 0.00% | Oct 2026 |
| Dimensional US Small Cap ETF | 32.4K | 0.08% | 0.00% | Oct 2026 |
| Avantis US Small Cap Equity ETF | 30.6K | 0.07% | 0.00% | Oct 2026 |
Top institutions holding OKUR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| RA Capital Management, LLC | 4.00M | 9.71% | 0.00% | Jun 2026 |
| Bvf Inc | 3.24M | 7.86% | +63.51% | Jun 2026 |
| StepStone Group LLC | 2.66M | 6.46% | 0.00% | Jun 2026 |
| ADAR1 Capital Management LLC | 2.24M | 5.44% | -8.06% | Jun 2026 |
| Vivo Capital, LLC | 1.93M | 4.68% | 0.00% | Jun 2026 |
| Vestal Point Capital LP | 1.83M | 4.43% | -0.77% | Jun 2026 |
| BlackRock Inc | 1.50M | 3.64% | +2,924.67% | Jun 2026 |
| Trails Edge Capital Partners, LP | 1.44M | 3.49% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.44M | 3.49% | +146.71% | Jun 2026 |
| Prosight Management, LP | 1.33M | 3.22% | +35.40% | Sep 2026 |
| Adage Capital Partners Gp LLC | 1.20M | 2.93% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 1.19M | 2.88% | +3,058.13% | Jun 2026 |
| Sio Capital Management, LLC | 1.08M | 2.62% | 0.00% | Jun 2026 |
| Logos Global Management LP | 964K | 2.34% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 724K | 1.76% | +633.61% | Jun 2026 |
| NEA Management Company, LLC | 479K | 1.16% | 0.00% | Jun 2026 |
| State Street Corp | 464K | 1.13% | +3,344.23% | Jun 2026 |
| Ensign Peak Advisors Inc | 432K | 1.05% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 353K | 0.86% | -1.56% | Sep 2026 |
| Sofinnova Ventures | 322K | 0.78% | +127.02% | Jun 2026 |
OnKure Therapeutics, Inc. company profile
- Company name
- OnKure Therapeutics, Inc.
- Ticker
- OKUR.US
- Exchange
- USA Stocks
- Listed since
- Oct 7, 2024
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 45
- Fiscal year end
- December
- Address
- 6707 Winchester Circle, Boulder, CO, United States, 80301
- Phone
- 720-307-2892
- Website
- onkuretherapeutics.com
About OnKure Therapeutics, Inc.
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.
OnKure Therapeutics, Inc. management
10- Dr. Nicholas A. Saccomano Ph.D.President, CEO & Director · born 1959
- Mr. Jason A. Leverone CPAChief Financial Officer · born 1974
- Dr. Isaac Manke Ph.D.Senior VP of Business Development & Director · born 1977
- Dr. Samuel Agresta M.D., M.P.H.Chief Medical Officer · born 1973
- Dr. Dylan Hartley Ph.D.Chief Scientific Officer · born 1969
- Mr. Rogan P. Nunn J.D.General Counsel & Secretary
- Dr. James Blake Ph.D.Senior Vice President of Computational Drug Discovery
- Dr. Kevin S. Litwiler Ph.D.Senior Vice President of DMPK & Clinical Pharmacology
- Dr. Mark L. Boys Ph.D.Senior Vice President of Discovery Chemistry
- Ms. Roberta AltonSenior Vice President of Clinical Operations